Page last updated: 2024-08-17

quinoxalines and yf 476

quinoxalines has been researched along with yf 476 in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Allison, B; Barrett, TD; Cagnon, L; Figueroa, K; Freedman, J; Ghoos, E; Lagaud, G; Li, L; Moreno, V; Morton, MF; Prendergast, CE; Pyati, J; Rabinowitz, MH; Rizzolio, MC; Shankley, NP; Ver Donck, L; Wu, X1
Janakiram, NB; Lightfoot, S; Madka, V; Mohammed, A; Pathuri, G; Rao, CV; Ritchie, R; Singh, A; Stratton, N; Suen, C1

Other Studies

2 other study(ies) available for quinoxalines and yf 476

ArticleYear
JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailability.
    The Journal of pharmacology and experimental therapeutics, 2011, Volume: 338, Issue:1

    Topics: Administration, Oral; Animals; Benzodiazepinones; Biological Availability; Caco-2 Cells; CHO Cells; Cricetinae; Cricetulus; Dogs; Dose-Response Relationship, Drug; Female; Guinea Pigs; Humans; Male; Mice; Phenylurea Compounds; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptor, Cholecystokinin B; Species Specificity; Sulfonamides

2011
Targeting cholecystokinin-2 receptor for pancreatic cancer chemoprevention.
    Molecular carcinogenesis, 2019, Volume: 58, Issue:10

    Topics: Adenocarcinoma; Animals; Benzodiazepinones; Carcinoma in Situ; Carcinoma, Pancreatic Ductal; Chemoprevention; Disease Models, Animal; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Neoplasm Proteins; Pancreatic Neoplasms; Phenylurea Compounds; Proto-Oncogene Proteins p21(ras); Quinoxalines; Receptor, Cholecystokinin B; Signal Transduction; Sulfonamides

2019